Impact of newly diagnosed prostate cancer at time of evaluation for renal transplantation.
chronic
kidney failure
kidney transplantation
prostatic neoplasms
waiting lists
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
06
04
2023
received:
25
09
2022
accepted:
14
04
2023
medline:
8
9
2023
pubmed:
4
5
2023
entrez:
4
5
2023
Statut:
ppublish
Résumé
Systematic screening for prostate cancer is widely recommended in candidates for renal transplant at the time of listing. There are concerns that overdiagnosis of low-risk prostate cancer may result in reducing access to transplant without demonstrated oncological benefits. The objective of the study was to assess the outcome of newly diagnosed prostate cancer in candidates for transplant at the time of listing, and its impact on transplant access and transplant outcomes according to treatment options. This retrospective study was conducted over 10 years in 12 French transplant centers. Patients included were candidates for renal transplant at the time of prostate cancer diagnosis. Demographical and clinical data regarding renal disease, prostate cancer, and transplant surgery were collected. The primary outcome of the study was the interval between prostate cancer diagnosis and active listing according to treatment options. Overall median time from prostate cancer diagnosis to active listing was 25.0 months [16.4-40.2], with statistically significant differences in median time between the radiotherapy and the active surveillance groups (p = .03). Prostate cancer treatment modalities had limited impact on access and outcome of renal transplantation. Active surveillance in low-risk patients does not seem to compromise access to renal transplantation, nor does it impact oncological outcomes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14998Informations de copyright
© 2023 The Authors. Clinical Transplantation published by John Wiley & Sons Ltd.
Références
Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. The Lancet. 1999;354(9173):93-99. doi:10.1016/S0140-6736(99)06154-1
Rodríguez Faba O, Boissier R, Budde K, et al. European association of urology guidelines on renal transplantation: update 2018. Eur Urol Focus. 2018;4(2):208-215. doi:10.1016/j.euf.2018.07.014
Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243-262. doi:10.1016/j.eururo.2020.09.042
Abramowicz D, Cochat P, Claas FHJ, et al. European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care. Nephrol Dial Transplant. 2015;30(11):1790-1797. doi:10.1093/ndt/gfu216
Wyld M, Morton RL, Hayen A, Howard K, Webster AC. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Med. 2012;9(9):e1001307. doi:10.1371/journal.pmed.1001307
Culty T, Goujon A, Defortescu G, et al. Recommandations françaises du Comité de transplantation de l'Association française d'urologie (CTAFU): cancer de la prostate localisé chez le patient transplanté rénal ou en attente de transplantation. Progrès en Urologie. 2021;31(1):4-17. doi:10.1016/j.purol.2020.04.027
Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of cancer risk among U.S. solid organ transplant recipients: the transplant cancer match study. JAMA. 2011;306(17):1891-1901. doi:10.1001/jama.2011.1592
Viecelli AK, Lim WH, Macaskill P, et al. Cancer-specific and all-cause mortality in kidney transplant recipients with and without previous cancer. Transplantation. 2015;99(12):2586-2592. doi:10.1097/TP.0000000000000760
Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6):905-913. doi:10.1111/j.1600-6143.2004.00450.x
Kessler M, Jay N, Molle R, Guillemin F. Excess risk of cancer in renal transplant patients. Transplant International. 2006;19(11):908-914. doi:10.1111/j.1432-2277.2006.00383.x
Brattström C, Granath F, Edgren G, Smedby KE, Wilczek HE. Overall and cause-specific mortality in transplant recipients with a pretransplantation cancer history. Transplantation. 2013;96(3):297-305. doi:10.1097/TP.0b013e31829854b7
Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190(2):419-426. doi:10.1016/j.juro.2013.04.119
Wada Y, Nakanishi J, Takahashi W, et al. Mass screening for prostate cancer in patients with end-stage renal disease: a comparative study. BJU International. 2006;98(4):794-797. doi:10.1111/j.1464-410X.2006.06374.x
Chen CJ, Heldt JP, Anderson KM, et al. Prostate specific antigen levels and prostate cancer detection rates in patients with end stage renal disease. J Urol. 2012;187(6):2061-2065. doi:10.1016/j.juro.2012.01.082
Boissier R, Hevia V, Bruins HM, et al. The risk of tumour recurrence in patients undergoing renal transplantation for end-stage renal disease after previous treatment for a urological cancer: a systematic review. Eur Urol. 2018;73(1):94-108. doi:10.1016/j.eururo.2017.07.017
Al-Adra DP, Hammel L, Roberts J, et al. Pre-transplant solid organ malignancy and organ transplant candidacy: a consensus expert opinion statement. Am J Transplant. 2021;21(2):460-474. doi:10.1111/ajt.16318
Bieri U, Hübel K, Seeger H, et al. Management of active surveillance-eligible prostate cancer during pretransplantation workup of patients with kidney failure: a simulation study. CJASN. 2020;15(6):822-829. doi:10.2215/CJN.14041119
Stöckle M, Junker K, Fornara P. Low-risk prostate cancer prior to or after kidney transplantation. Eur Urol Focus. 2018;4(2):148-152. doi:10.1016/j.euf.2018.07.003
Woodle ES, Gupta M, Buell JF, et al. Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc. 2005;37(2):958-959. doi:10.1016/j.transproceed.2004.12.127
Agence de la biomédecine. Accessed July 14, 2022. https://rams.agence-biomedecine.fr/greffe-renale-0
Liauw SL, Ham SA, Das LC, et al. Prostate cancer outcomes following solid-organ transplantation: a SEER-Medicare analysis. J Natl Cancer Inst. 2019;112(8):847-854. doi:10.1093/jnci/djz221
Tosoian JJ, Mamawala M, Epstein JI, et al. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol. 2015;33(30):3379-3385. doi:10.1200/JCO.2015.62.5764
Al Jurdi A, Gilligan H, Cohen-Bucay A. Delaying kidney transplantation in patients with prostate cancer: is it warranted? Kidney Med. 2021;3(6):893-895. doi:10.1016/j.xkme.2021.09.002
Vitiello GA, Sayed BA, Wardenburg M, et al. Utility of prostate cancer screening in kidney transplant candidates. JASN. 2016;27(7):2157-2163. doi:10.1681/ASN.2014121182
Pettenati C, Jannot AS, Hurel S, et al. Prostate cancer characteristics and outcome in renal transplant recipients: results from a contemporary single center study. Clin Transplant. 2016;30(8):964-971. doi:10.1111/ctr.12773
Felber M, Drouin SJ, Grande P, et al. Morbidity, perioperative outcomes and complications of robot-assisted radical prostatectomy in kidney transplant patients: a French multicentre study. Urol Oncol. 2020;38(6):599.e15-599.e21. doi:10.1016/j.urolonc.2019.12.017